# National Institute of Allergy and Infectious Diseases (NIAID): Phase 1 study closed enrollment, 105 enrolled (HIV-1)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
| Study | A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy |
| NCT ID | NCT05612178 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | HIV-1 |
| Intervention types | biological, other |
| Target enrollment | 105 |
| Site countries | United States |
| Posted | 2022-11-10 |
| Planned start | 2023-07-26 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-01 |
| Last update posted | 2026-10-01 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- 105 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05612178). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.